Management review is the point at which the people who run the company look at the quality system as a whole, decide whether it is working, and commit resources and decisions to fixing what is not. It is the one meeting that EU GMP and ICH Q10 both describe in detail, and it is the meeting the inspector uses to decide whether senior management owns quality or has delegated it to the QA department.
That last point is why it matters more than its length on the agenda suggests. A deviation system can be run well by QA on its own. A management review cannot. If the site head is absent, the inputs are thin or the outputs are vague, the inspector concludes that the requirement for senior management responsibility is not met, and that conclusion colours everything else they read.
What EU GMP and ICH Q10 say
EU GMP Chapter 1 puts it plainly. Paragraph 1.5 states that senior management has the ultimate responsibility to ensure an effective pharmaceutical quality system is in place, adequately resourced, with roles, responsibilities and authorities defined, communicated and implemented. Paragraph 1.6 requires periodic management review, with the involvement of senior management, of the operation of the pharmaceutical quality system to identify opportunities for continual improvement of products, processes and the system itself. Chapter 2, paragraph 2.1, adds that senior management should determine and provide adequate and appropriate resources to implement and maintain the system. PIC/S PE 009 Chapter 1 carries the same text, so the expectation is identical across the PIC/S membership.
ICH Q10 gives the most detail. Section 2 is titled management responsibility and runs from 2.1 (management commitment) through 2.2 (quality policy), 2.3 (quality planning), 2.4 (resource management), 2.5 (internal communication), 2.6 (management review) and 2.7 (management of outsourced activities and purchased materials). Section 3.2.4 describes management review of process performance and product quality, with lists of inputs and outputs. Sections 4.1 to 4.4 describe management review of the quality system itself: measuring achievement of the system's objectives, assessing performance indicators, monitoring internal and external factors, and the outcomes that should follow.
Who must be in the room
Both documents name the participant as senior management, which at a manufacturing site means the site head and their direct reports. ICH Q10 2.1 expects senior management to participate in the design, implementation, monitoring and maintenance of the system, and 2.6 expects them to be the ones reviewing it.
Delegation is the most common failure. The site head is on the distribution list, a deputy attends, and the head signs the minutes a fortnight later. An inspector will ask who chaired the review, who attended and who made the decisions, and will compare the answer with the organisation chart. If the person accountable for the site was not present when the site's quality was reviewed, the finding writes itself.
How often
EU GMP says periodic. ICH Q10 2.6 makes the review the mechanism of senior management governance without naming an interval, and PIC/S PE 009 repeats the EU text. None of them gives a number, which means the number is yours to justify. Annual is the minimum most sites choose for the full formal review, but a system that produces a recall, a critical inspection finding or a failing supplier in month two cannot wait until month twelve. The defensible pattern is a full review at least annually, a shorter quarterly review of metrics and open actions, and a documented trigger for an unscheduled review when something serious happens.
What the inspector actually tests
Inspectors rarely read the minutes first. They start from something they have already found, a repeated deviation, a complaint trend, a late CAPA, and trace it upwards. The questions are predictable.
- Was this problem visible to senior management? If the complaint trend was rising for three quarters, does any review pack show it?
- Did the review decide anything about it? Discussion is not a decision. The minutes must show what was concluded.
- Did the decision come with resources? A decision to reduce deviations with no budget, headcount or time is a wish.
- Was the action closed, and did it work? The next review should show the status of the action and the effect on the metric.
- Would the site head be able to describe the problem without the QA head's help? Inspectors ask senior managers direct questions for exactly this reason.
Why 'the review is a formality' is a finding, not an opinion
The words inspectors use are 'no evidence of management awareness' or 'management review not effective'. Both are findings against the pharmaceutical quality system rather than against a procedure, and in EU inspection data and EudraGMDP non-compliance statements the quality system category is consistently among the largest. A review that meets on time, with the right people, but that does not change anything, satisfies the letter of 1.6 and fails its purpose, which is continual improvement. Inspectors know the difference and their reports say so.
Module 1 of the course sets out the requirements side by side across EU GMP and ICH Q10, and then works through three real review cycles to show which one would generate a finding and why.